The process of inducing somatic mutations that selectively alter the sequence and specificity of the B cell receptor.
Immune cells produced in the bone marrow undergo a process of quality control, known as immune tolerance, that occurs throughout the life of B and T cells and that carefully selects useful protective immune cells while eliminating or neutralizing potentially harmful self-reactive cells 1 . The elimination or reprogramming of self-reactive B cells through B cell receptor (BCR) editing takes place during B cell development in the bone marrow, during B cell maturation in the spleen and most probably after B cell activation, following affinity maturation in the germinal centre 2 . The nature of BCR engagement 3 and the availability of survival cytokines, such as interleukin-7 (IL-7) and B cell activating factor (BAFF; also known as TNFSF13B, BLyS or TALL1), are key determinants of whether developing B cells will survive or die during the establishment of tolerance 1 . Thus, the balance between antigen receptordriven stimuli and signals from survival cytokines controls the quality of most emerging immune cells. It was therefore tempting to assume that the autoimmune symptoms that are observed in mice that overexpress BAFF are due to the rescue of autoreactive B cells from deletion. In this Review, we propose that this is unlikely to be the only possible explanation for the association between BAFF and autoimmunity; new evidence implicates BAFF in the pathogenic T cell-independent activation of low-affinity self-reactive B cells. At a time when BAFF antagonists are being actively tested in clinical trials for the treatment of autoimmunity and lymphomas, this Review also summarizes our knowledge of how BAFF and its closely related homologue APRIL (a proliferation-inducing ligand; also known as TNFSF13) activate their receptors and transmit survival and growth signals to B cells.
Ligands in the BAFF system
The tumour necrosis factor (TNF)-family members BAFF and APRIL are homotrimeric type II trans membrane proteins. A membrane-bound form of APRIL, TWE-PRIL (also known as TNFSF12-TNFSF13), is generated by trans-splicing of the adjacent TWEAK (TNF-related weak inducer of apoptosis; also known as TNFSF12) and APRIL genes 4 , but little is known about the physiological function of TWE-PRIL.
BAFF and APRIL are proteolytically processed at furin consensus sequences to produce soluble cytokines (FIG. 1) . Membrane-bound APRIL is processed efficiently into soluble ligands 4 , which explains why epitopes located before and after the processing site fail to colocalize by immunohistochemistry 5, 6 . BAFF, however, can also be found in a membrane-bound form. In myeloid cells, the binding of immune complexes increased BAFF processing in a manner that was dependent on the expression of high-affinity Fc receptor for IgG (FcγRI) 7 . Processed, soluble BAFF adopts the usual trimeric form of a TNF-family ligand, but it is the only member of the family that can also further assemble as an ordered, capsid-like structure comprising twenty trimers. The receptor-binding sites remain exposed and accessible at the surface of BAFF 60-mers, as shown by crystallography 8 . Heteromers of BAFF and APRIL have also been described 4 .
Receptors in the BAFF system BAFF and APRIL both bind to the receptors B cell maturation antigen (BCMA; also known as TNFRSF17) and transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI; also known as TNFRSF13B), and BAFF also binds to BAFF receptor (BAFFR; also known as BR3 or TNFRSF13C) 4, 9 . Systematic mutagenesis studies of the relevant portions of TACI, BCMA and BAFFR have identified essential determinants of ligand binding as well as residues that account for the lack of interaction between APRIL and BAFFR and for the weak binding of BAFF to BCMA 10 (reviewed in ReFS 4, 9) . In addition to TACI and BCMA, APRIL also interacts with the polysaccharide side chains of heparan sulphate proteoglycans (HSPGs) (FIG. 1a) . This interaction is mediated by basic residues of APRIL and does not interfere with binding to either TACI or BCMA 11, 12 . It is noteworthy that HSPG-bound APRIL is biologically active 5, 13 . TACI exists as two splice variants containing a highaffinity ligand-binding site preceded or not by a lowaffinity binding site of unknown relevance 10 . Similarly to APRIL, TACI interacts with proteoglycans such as syndecans 14 , which are expressed on the surface of many mesenchymal cells but also on activated macrophages and antibody-secreting cells. Syndecans might function , and their binding to BAFF receptor (BAFFR), transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and B cell maturation antigen (BCMA). BAFF and APRIL are synthesized as membrane-bound proteins that can be released as soluble cytokines by proteolytic cleavage. Soluble BAFF exists as homotrimers or as a capsid-like assembly of 20 trimers (60-mer). APRIL binds sulphated side chains of heparan sulphate proteoglycan (HSPG) at a site independent from bona fide receptor binding. TWE-PRIL, which contains the entire receptor-binding domain of APRIL, is described as a membrane-bound protein only. The arrows indicate interactions that can induce signalling, although BAFF trimer can also bind to TACI and BCMA. The dashed arrow indicates weak affinity of BAFF 60-mer for BCMA. b | Model of signalling induced by BAFF trimer and higher order oligomers. TNF receptor-associated factors (TRAFs) are trimeric intracellular signalling molecules that are recruited to three receptors held in the correct geometry by a trimeric ligand. Recruitment of TRAF3 to trimeric BAFFR leads to its degradation and releases the inhibition imposed by unbound TRAF3 on the alternative nuclear factor-κB2 (NF-κB2) signalling pathway. By contrast, recruitment of TRAF2 or TRAF6 to trimeric TACI results in a positive signal (classical NF-κB1 pathway) only when at least two trimeric TRAFs are recruited in response to higher order oligomers of ligand, such as BAFF 60-mers or APRIL cross-linked by HSPG.
Classical NF-κB pathway
An IKKγ (inhibitor of nuclear factor-κB (NF-κB) kinase-γ)-dependent signalling pathway that activates the transcription factor NF-κB, which usually contains the p50 subunit derived from the p105 NF-κB1 precursor.
Alternative NF-κB pathway
A signalling cascade resulting in the IKKγ (inhibitor of nuclear factor-κB (NF-κB) kinase-γ)-independent activation of the transcription factor NF-κB. Hallmarks of this pathway are the activation of NF-κB-inducing kinase and the processing of NF-κB2 from a p100 precursor to a p52 fragment.
as local activators of APRIL 5, 13 , as ligands that activate signalling through TACI 14 or as direct providers of signals to antibody-secreting cells 15 . until recently, it was unclear whether the low-affinity binding of BAFF to BCMA was physiologically relevant. However, BCMA-dependent plasma cells in the bone marrow disappear if both APRIL and BAFF are removed by the administration of a TACI-Fc fusion protein, but the number of these cells is not affected by selective removal of either BAFF alone (by administration of BAFFR-Fc) or APRIL alone (in April -/-mice) 16 . This indicates that BCMA can deliver relevant signals in response to ligation by both BAFF and APRIL in vivo. The weak interaction between BAFF and BCMA is most probably stabilized by avidity effects 17 .
Signal transduction by ligand oligomerization
A trimeric ligand such as BAFF or APRIL binds to three independent receptors to initiate signalling 8, 10 . Because more than one receptor is required to transmit the signal, the system is susceptible to dominant effects of mutations, as is probably the case in patients with common variable immunodeficiency (CvID) harbouring heterozygous TACI mutations 18, 19 
Binding of a trimeric ligand to its cognate receptors does not, however, necessarily result in productive signalling. This is particularly apparent for TACI-dependent signals in response to APRIL stimulation in primary B cells. A single trimer of APRIL binds to TACI, but APRIL is essentially inactive unless it is further multimerized, for example by binding to HSPG 12, 13 . Similarly, BAFF 60-mers but not BAFF trimers signal through TACI, although both forms of BAFF can initiate BAFFRmediated effects 20 . These in vitro data show that signalling through TACI requires multimeric ligands such as BAFF 60-mers, HSPG-bound APRIL or membrane-bound ligands, but not soluble, trimeric ligands. Similar conclusions were reached for TACI expressed by monocytes and dendritic cells 21, 22 .
The observed requirement for oligomeric ligands to induce signalling through TACI fits with a model in which intracellular signalling molecules are recruited on adjacent ligand-receptor complexes (FIG. 1b) . TNF receptor-associated factors (TRAFs) are trimeric intracellular proteins that bind linear TRAF-binding sequences present in several receptors, including BCMA, TACI and BAFFR. The affinity of TRAFs for a monomeric receptor is low, but the interaction is greatly stabilized by avidity effects when the TRAF trimer binds to three receptors held in the correct geometry by the ligand 23 . TRAF2 and TRAF6 bind to TACI and potently activate the transcription factor nuclear factor-κB (NF-κB) if at least two trimeric TRAF molecules are held in close proximity 24 , a state that can be achieved when at least six receptors are recruited (FIG. 1b) . The situation is probably different for BAFFR, which selectively recruits TRAF3 for the purpose of degrading it, thereby shortcutting the need for higher order receptor clustering to obtain an effect [25] [26] [27] (FIG. 1b) .
The early steps of BAFFR signalling have long remained elusive because BAFFR binds only TRAF3, which by itself does not activate the classical NF-κB pathway or the alternative NF-κB pathway. TRAF3 interacts with NF-κB-inducing kinase (NIK), the upstream kinase responsible for NF-κB2 processing, and induces NIK degradation 28 , resulting in decreased NF-κB2 activation. Targeted deletion of TRAF3 (and/or TRAF2) in B cells leads to constitutive activation of NF-κB2, recapitulating the effect of constant activation of BAFFR 25 . Although TRAF2 does not interact directly with BAFFR, its deletion induces TRAF3 accumulation 25 . These observations form the basis for a model that rationalizes the early steps of BAFFR signalling: in the absence of BAFF, TRAF3 binds to NIK and, with the help of TRAF2, induces NIK degradation by the proteasome, thus preventing the activation of the alternative NF-κB pathway. In the presence of BAFF, TRAF3 is recruited to BAFFR and degraded in a TRAF2-dependent manner, resulting in the stabilization of NIK and activation of NF-κB2, which then leads to increased B cell survival 29, 30 (FIG. 2) .
Box 1 | TACI and BAFFR in CVID
Common variable immunodeficiency (CVID) is characterized by a marked hypogammaglobulinaemia and impaired responses to vaccination, resulting in susceptibility to bacterial infections. CVID is diagnosed after exclusion of other causes of hypogammaglobulinaemia and, in contrast to other primary immunodeficiencies, generally develops late in life. About 20% of patients with CVID have signs of autoimmunity and/or lymphoproliferation 106 . Mutations in inducible T cell co-stimulator (ICOS) or the B cell co-receptor CD19 are occasionally found in patients with CVID, but not as frequently as mutations in transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI), which affect 8% of patients with CVID. Mutation of both TACI alleles is always associated with insufficient antibody production and, frequently, with CVID 106 . Heterozygous TACI mutations resulting in a substitution of cysteine at position 104 with arginine (Cys104Arg) and alanine at position 181 with glutamic acid (Ala181Glu) 107 predispose to CVID instead of actually causing the disease. This is illustrated by the following observations: 2% of the control population carry a mutant TACI allele 106 ; CVID develops most of the time in the absence of TACI mutations; a heterozygous TACI mutation (Ala181Glu) did not segregate with disease in one familial case of CVID 106 ; and in the case of two brothers with a homozygous TACI mutation (Ser144X; in which X denotes a stop codon), one was affected with CVID but the other had hypogammaglobulinaemia with no clinical signs of immunodeficiency, indicating that other genetic or environmental factors are required to induce CVID 19 . Humans lacking TACI expression have increased numbers of B cells (as observed in Taci -/-mice), but decreased immunoglobulin levels (unlike Taci -/-mice), suggesting that TACI has a crucial role in immunoglobulin production in humans but not in mice. One patient with CVID lacking transmembrane B cell activating factor receptor (BAFFR; also known as BR3 or TNFRSF13C) was reported with a severe B cell lymphopenia 108 . If it can be confirmed that the mutation in BAFFR causes the phenotype, it could indicate that human B cells, similarly to mouse B cells, strongly rely on BAFF signals for their survival. Nature Reviews | Immunology 
Cytotrophoblast
A cell of the inner layer of the trophoblast, which is the outermost layer in an embryo that functions to anchor the embryo to the maternal endometrium.
Marginal zone B cell
A B cell that resides in the marginal zone, a region at the interface between the non-lymphoid red pulp and the lymphoid white pulp of the spleen.
B1 B cell
A cell belonging to a sub-class of B cells that reside mainly in the peritoneal and pleural cavities, that express IgM in greater quantities than IgG and the receptors of which are polyspecific (that is, they have low affinities for many different antigens).
In summary, signalling in the BAFF system is determined not only by the specificity of BAFF and APRIL for their respective receptors, but also by the form in which these ligands are presented to receptors. 35 and B cell chronic lymphocytic leukaemia (BCLL) cells can also produce BAFF and APRIL and, in the case of BCLL, this contributes to tumour cell survival 36 . The production of BAFF and APRIL by innate immune cells and some lymphocytes supports ongoing immune responses.
Expression of BAFF, APRIL and their receptors
A recent development in the field is the identification of non-haematopoietic cells expressing BAFF and/or APRIL. These include cytotrophoblasts in the placenta 37 , fibroblast-like synoviocytes in the synovium of patients with rheumatoid arthritis 38 , osteoclasts in patients with multiple myeloma 39, 40 , epithelial cells in tonsils 5 and airways 41 , salivary gland epithelial cells in patients with Sjögren's syndrome 42 , breast adipocytes 43 , and carcinoma cells 43 or astrocytes in patients with primary central nervous system lymphomas or multiple sclerosis, respectively 44, 45 . The production of BAFF and APRIL by non-haematopoietic cells might provide local niches to modulate the survival and function of B cells and plasma cells in health and disease.
The receptors for BAFF and APRIL are mainly expressed by B cells 46, 47 . In mice, the expression of BAFFR is low on newly formed immature B cells, but increases as these cells progress through the stages of B cell maturation and is eventually expressed by all mature B cells 46 . TACI is expressed by all peripheral B cells and particularly marginal zone B cells and B1 B cells (reviewed in ReF. 48) , and BCMA expression is restricted to antibody-producing cells 49 . In humans, BAFFR is widely expressed by all B cells except for bone marrow plasma cells 46, 47 . TACI is expressed by CD27 + memory B cells, by tonsillar and bone marrow plasma cells, by a subpopulation of activated CD27 -non-germinal centre cells 46, 47, 50 and by a small subset of naive B cells in the blood and tonsils 46 , which is consistent with the idea that, similar to the mouse system 94 , TACI is an inducible receptor in humans. BCMA is expressed by human plasma cells from tonsils, spleen and bone marrow 46 , but also by tonsillar memory B cells and by germinal centre B cells, which have a TACI -BAFFR low phenotype 47 . Regarding non-B cells, BAFFR expression is upregulated by T cells after activation 34 and BAFFR is constitutively expressed by regulatory T cells 34 ; TACI is expressed by monocytes 21 and DCs
22
. These results indicate that the role of BAFF and APRIL extends beyond that of B cell biology, although so far little is known of the potential effects.
The phenotype of deficient mice In the periphery, and possibly in the bone marrow, newly formed immature B cells differentiate to immature transitional type 1 (T1), type 2 (T2) and/or type 3 (T3) cells before becoming mature follicular or marginal zone B cells 51 (FIG. 3) . The nature of the BCR determines whether a B cell becomes follicular or marginal zone, a decision that is taken at the T2 stage 52 , or even as early as the T1 stage 53 (FIG. 3) . A role for BAFF and BAFFR in the survival of B cells during B cell maturation was shown in BAFF-and BAFFR-deficient animals, in which maturation of marginal zone and B2 cells is impaired beyond the T1 stage 31 (TABLe 1) . However, B1 B cells, memory B cells and a small population of mature splenic B cells do not require BAFF or APRIL for survival 16, 31, [54] [55] [56] (FIG. 3) . B cell maturation in April -/-mice is normal (reviewed in ReF. 4 ), but class switching to IgA in two independent April -/-mouse strains is impaired 4, 57 . Indeed, APRIL is important for the survival of class-switched mouse B cells 58 . Specifically, APRIL and BAFF mediate CD40-independent class switching to IgA through both TACI and BAFFR 59, 60 , and binding of APRIL to HSPGs might be crucial in this respect because treatment of B cells with heparitinase abrogated the class-switching response to APRIL 15 . Furthermore, in humans, intestinal epithelial cells produce APRIL in , NF-κB-inducing kinase (NIK) forms a complex with TNF receptor-associated factor 2 (TRAF2) and TRAF3. TRAF2 recruits cellular inhibitor of apoptosis (cIAP), which targets NIK for degradation by ubiquitylation, thereby inhibiting the alternative nuclear factor-κB2 (NF-κB2) signalling pathway. b | Following BAFF trimer binding to BAFFR, TRAF3 is recruited to the receptor and TRAF2 promotes TRAF3 degradation. NIK is free to mediate the activation of the alternative NF-κB2 signalling pathway, which promotes cell survival. Ub, ubiquitin. Nature Reviews | Immunology These cells also produce thymic stromal lymphopoietin that is sensed by DCs in the lamina propria, which then release APRIL 61, 62 . In the bone marrow, APRIL favours the establishment and/or the survival of plasmablasts, and lack of APRIL expression in the bone marrow of newborn mice might explain why antibody responses in neonates are short-lived 58 . With time, however, long-lived plasma cells accumulate to normal levels in APRIL-deficient mice 16, 63 , indicating a redundant role for BAFF and APRIL in this process or the existence of additional factors that support the growth of bone marrow plasma cells.
TACI has both positive and negative roles in the regulation of mouse B cell development. on the one hand, TACI-deficient mice have excessive numbers of B cells, indicating that TACI negatively regulates the size of the B cell compartment in vivo (reviewed in ReF. 48) . on the other hand, TACI is required for efficient T cellindependent type II humoral immune responses 48 . As TACI is strongly expressed by innate B cells (including marginal zone and B1 cells) that are known to participate in T cellindependent type II immune responses, it is probable that it provides positive signals for the maturation or survival of plasmablasts derived from these cells 64 .
Bcma
-/-mice are healthy, although the survival of long-lived bone marrow plasma cells is impaired in these mice 49 . BCMA can also promote the antigen-presenting function of B cells 65 , although BAFF-mediated upregulation of MHC class II expression was also achieved by signalling through TACI and BAFFR 20 . In summary, studies of deficient mouse strains have shown us that: BAFF and BAFFR control the development and survival of B2 and marginal zone B cells; APRIL regulates aspects of CD40-independent class switching and promotes plasma cell survival; TACI helps humoral immune responses of innate B cells to repetitive antigens and somehow regulates the expansion of the B cell pool; and BCMA contributes to the maintenance of plasma cells. B cell memory, however, does not rely on the BAFF and APRIL system 16 . To what extent these findings in rodents can be extrapolated to humans remains to be determined. . A similar population has been described in the intestine, which in this case requires BAFF for survival 113 . B cell subsets circled in red require BAFF for development and survival. NF, newly formed.
mTOR complex 1
A multiprotein complex containing mammalian target of rapamycin (mTOR), which functions as a nutrient, energy and redox sensor and controls protein synthesis. The activity of this complex is stimulated, among others, by insulin, growth factors and amino acids.
BAFF-induced signals
Stimulation of BAFFR potently activates the alternative NF-κB2 pathway and weakly activates the classical NF-κB1 pathway in primary B cells, whereas TACI is a potent stimulator of the classical NF-κB1 pathway (FIG. 4) (reviewed in ReF. 48) . Both NF-κB pathways are required for B cell survival, which can be sustained by signalling through BAFFR alone 48 . TACI signalling is important for specific B cell types 64 and could also reinforce BAFFR signals, but the relative contributions of BAFFR and TACI to BAFF-mediated signalling have not been systematically addressed in the studies cited below.
NF-κB activation downstream of BAFF has been linked to increased expression of anti-apoptotic proteins, to integrin-mediated localization of B cells in the marginal zone and to T cell-independent antibody class switching (reviewed in ReF. 48 ). BAFF not only induces the survival of B cells, but also promotes glycolysis, protein synthesis and cell growth, in part through the activation of the protein kinase mammalian target of rapamycin (mToR; also known as FRAP1) in the context of mTOR complex 1 (mToRC1) 66, 67 (FIG. 4) . The protein kinase AKT1 is an important intermediate between BAFF and mToR. Briefly, BAFF-induced signalling activates phosphoinositide 3-kinase (PI3K) through a pathway that remains to be defined. This results in the accumulation of the lipid phosphatidylinositol-3,4,5-trisphosphate (PtdIns(3,4,5) P 3 ) and membrane recruitment of phosphoinositidedependent protein kinase 1 (PDK1) and AKT1 (also known as PKB). AKT1 is phosphorylated, and thereby activated, at Thr308 by PDK1 and at a second activation site (Ser473) by protein kinase Cβ (PKCβ) 66 and/or by mToRC2 (ReF. 67) and can then relieve the inhibition of mToRC1. Two well-characterized targets of mToRC1 Baff-transgenic mice
• Development of B cell hyperplasia from the T2 B cell stage • Development of T cell-independent but MyD88-dependent autoimmunity involving the production of autoantibodies, glomerulonephritis, inflammation and destruction of the salivary glands are S6 kinase 1 (S6K1; also known as RBS6KB1) and the eukaryotic initiation factor 4E (EIF4E) binding protein 1 (4EBP1; also known as EIF4EBP1). Phosphorylated S6K1 activates ribosomes and increases the capacity for protein synthesis, and phosphorylated 4EBP1 releases EIF4E, which promotes mRNA translation 66 . 4EBP1 is also a target of PIM2, a kinase that is induced by NF-κB2 (ReF. 68 ).
Simultaneous inactivation of mToRC1 (with rapamycin) and PIM2 (in Pim2
-/-mice, which otherwise have normal B cells) rendered B cells unresponsive to BAFF in terms of both survival and growth, implying that these two kinases are involved in transducing BAFF-mediated signals 67 , although a clarification of the role of PIM2 by independent studies is required. The effect on growth 66 and/or mammalian target of rapamycin complex 2 (mTORC2). mTORC1 is activated by the PI3K-AKT1 pathway, whereas activation of the kinase PIM2 is induced by the alternative nuclear factor-κB2 (NF-κB2) pathway, although the involvement of PIM2 in the response to BAFF awaits confirmation by independent studies. mTORC1 and PIM2 seem to have redundant roles in activating mRNA translation and cell growth. Two targets of mTORC1 are S6 kinase 1 (S6K1) and the eukaryotic initiation factor 4E (EIF4E) binding protein 1 (4EBP1). Phosphorylated S6K1 activates ribosomes, and phosphorylated 4EBP1 releases EIF4E, which promotes mRNA translation. 4EBP1 is also a target of PIM2. MyC also promotes cell growth and could be at least partially under the control of BAFF through the classical NF-κB1 pathway. In addition to cell growth, BAFF promotes B cell survival by favouring a high ratio of myeloid cell leukaemia sequence 1 (MCL1), an anti-apoptotic member of the B cell lymphoma 2 (BCL-2) family, to BCL-2-interacting mediator of cell death (BIM), a pro-apoptotic antagonist of BCL-2 family members. This control is achieved at the transcriptional level (through cyclic AMP responsive element-binding protein (CREB) activation to enhance Mcl1 transcription, or through inhibiting forkhead box O3A (FOxO3A) to repress Bim transcription) and at the translational level (through the activation of EIF4E). In agreement with the negative regulation that BAFF and AKT1 impose on glycogen synthase kinase 3β (GSK3β) and PKCδ, these two kinases destabilize MCL1. Both AKT1 and PIM2 also inactivate the pro-apoptotic factor BCL-2-antagonist of cell death (BAD) by phosphorylation. The NF-κB pathway also controls the expression of integrins on marginal zone B cells and regulates T cell-independent class I switching (TI switch). NIK, NF-κB-inducing kinase; TACI, transmembrane activator and calcium modulator and cyclophilin ligand interactor; TRAF, TNF receptor-associated factor. 
Systemic lupus erythematosus

observed in Pim2
-/-mice treated with rapamycin could be due to inefficient protein synthesis in the combined absence of PIM2 and mToRC1, whereas lack of survival correlates with downregulation of myeloid cell leukaemia sequence 1 (MCL1).
MCL1 is a short-lived member of the B cell lymphoma 2 (BCL-2) family that is required for the development of haematopoietic stem cells and for the maintenance of peripheral B and T cells 69, 70 . The PI3K-AKT1 pathway (downstream of BAFF) positively regulates the transcription of Mcl1 (ReF. 71) , and active EIF4E promotes efficient translation of Mcl1 mRNA (as well as other mRNAs containing a GC-rich 5ʹ untranslated region) in B cells 72 . When mToRC1 was inactivated by the deletion of its positive regulator tuberous sclerosis protein 2 (TSC2), B cell tumours failed to grow as a result of lack of MCL1 expression 72 . In addition, MCL1-deficient B cells do not survive in response to BAFF 67 , demonstrating the crucial involvement of MCL1 in BAFF-mediated survival. The prosurvival role of other BCL-2-family members, such as the NF-κB targets BCL-X L or A1, in the response to BAFF is less clearly established. MCL1 acts by inhibiting the pro-apoptotic protein BCL-2-interacting mediator of cell death (BIM), which is an essential mediator of B cell death 73 . Finally, and in agreement with the negative regulation that BAFF and AKT1 impose on glycogen synthase kinase 3β (GSK3β) and PKCδ, these two kinases destabilize MCL1 (ReFS 74, 75) . It is also noteworthy that both AKT1 and PIM2 inactivate the proapoptotic factor BCL-2-antagonist of cell death (BAD) by phosphorylation.
By regulating the expression of numerous genes involved in metabolism, MyC is also involved in the control of B cell growth and renders B cells resistant to atrophy 76 . Interestingly, MyC is a direct target of the class ical NF-κB1 pathway and its expression also requires PI3K activity 76 , providing an additional link between BAFF-induced signalling and cell growth.
In conclusion, the activation of the alternative NF-κB2 and PI3K-AKT1-mToR pathways and the upregulation of expression of MCL1 provide a rational basis for the effects of BAFF on B cell survival and metabolic fitness.
BAFF in B cell homeostasis and tolerance
As a crucial survival factor for late transitional B cells 53 , BAFF has an important role in B cell homeostasis. APRIL has no or little role in this respect; its excessive production leads to the development of B1 B cell lymphomas in ageing April-transgenic mice, but it does not cause autoimmunity and has no immediate effect on B cell homeostasis (reviewed in ReF. 4) . For reasons that are still not fully clarified, B cell homeostasis depends on BAFF that is produced by radioresistant stromal cells rather than bone marrow-derived cells 55 . BAFFR is a positive regulator of B cell homeostasis because it transmits survival signals, whereas signalling through TACI decreases the size of the B cell pool. To do so, TACI could directly transmit inhibitory or apoptotic signals to B cells 48, 77 , or it could indirectly regulate the B cell pool by controlling the amount of BAFF that is available for signalling through BAFFR 20 or potentially the amount of TRAF molecules available to transmit BAFFR signals. There is also evidence that B cells exposed to TLR agonists upregulate the expression of BAFFR and TACI 78 , which somehow induce the expression of CD95 (also known as FAS) following BAFF-induced signalling, thereby sensitizing B cells to CD95-mediated killing 79 . The relative contributions of these different pathways to the negative regulatory effect of TACI on the B cell pool remain to be determined.
In a physiological setting, strongly self-reactive B cells compete with 'healthy' B cells for survival factors and for entry in the B cell follicle of lymphoid tissues (reviewed in ReF. 80 ). As BAFF promotes B cell survival, its overexpression could potentially break B cell tolerance by rescuing self-reactive B cells from deletion. However, the use of animal models mimicking the natural competition between healthy and self-reactive B cells has not revealed any catastrophic breakdown of B cell tolerance or massive escape of high-affinity autoreactive B cells in Baff-transgenic mice 81, 82 . In fact, strongly self-reactive B cells are deleted, become anergic or undergo receptor editing 1 before they start expressing BAFFR on the cell surface 82 , which explains the weak effect of BAFF on these cells. However, healthy B cells and low-affinity self-reactive B cells require a basal BCR signal to be positively selected [83] [84] [85] , as evidenced by the observation that deletion of the BCR in mature B cells led to their loss 84 ; the nature of this basal BCR signal remains unclear. So, the effect of excess BAFF seems to be on the positive selection and increased proliferation of low-affinity self-reactive B cells, mostly marginal zone B cells 53, 82 . In summary, the nature of the BCR on developing self-reactive B cells, the quality of its interaction with self antigen and the need to compete with healthy B cells are key determinants of whether excess BAFF will allow emergence of these cells into the mature B cell pool 81, 82, 86, 87 . Current data indicate that excess BAFF mainly supports the survival of low-affinity self-reactive B cells.
The role of BAFF in autoimmunity
Baff-transgenic mice develop severe autoimmune symptoms that are similar to systemic lupus erythematosus (SLE) and Sjögren's syndrome in humans (reviewed in ReF. 31) . However, as excessive BAFF production seems to support the survival of low-affinity self-reactive B cells in a complex B cell repertoire rather than resulting in a complete breakdown of B cell tolerance, can this event alone explain the devastating autoimmune disease that develops in Baff-transgenic mice? The current published literature on SLE agrees that the disease is mediated by several types of dysregulated immune cell: B cells, which can produce auto antibodies or present antigen to T cells; innate immune cells such as plasmacytoid DCs, which can produce high levels of stimulatory cytokines such as type I IFNs; and T cells, which are key players in the pathogenesis of SLE (reviewed in ReFS 88, 89) . Baff-transgenic mice have more effector T cells, but they also have a larger regulatory T cell compartment 50 . Furthermore, autoimmunity Nature Reviews | Immunology develops to the same extent in T cell-sufficent and T cell-deficient Baff-transgenic mice (FIG. 5) , the first described animal model of T cell-independent lupus 50 , which indicates that T cells are not responsible for the autoimmune disorder of Baff-transgenic mice. T cellindependent activation of self-reactive B cells is not unique to the Baff-transgenic model, as similar conclusions were reached in another mouse model of autoimmunity 90 . Collectively, these findings show that chronic activation or survival of T cell-independent low-affinity self-reactive B cells mediated by BAFF can lead to a form of SLE. This suggests that some patients with SLE might benefit from B cell-depleting or BAFF-antagonist therapies.
TLR signalling promotes BAFF effects through TACI.
In Baff-transgenic mice, the activity of B1 B cells is associated with nephritis, whereas marginal zone B cells do not infiltrate the inflamed kidneys but might have a role in the destruction of the salivary glands 91, 92 . Bafftransgenic mice that lack marginal zone B cells do not develop Sjögren's-like syndromes but they still develop severe nephritis 92 . However, nephritis does not develop in Baff-transgenic mice that have been reconstituted with MyD88-deficient B cells 50 . This indicates that activation of MyD88, possibly downstream of TLRs, leads to the production of pro-inflammatory autoantibodies that elicit complement activation and inflammation in the kidneys 50 (FIG. 5) . TACI might provide the DNA-specific and RNA-specific self-reactive B cells could therefore be activated directly through TLR9 and TLR7, respectively. Transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI; also known as TNFRSF13B) activation upregulates TLR expression, and TLR activation increases TACI expression. After TLR activation, and in the presence of high levels of BAFF, self-reactive B cells produce pro-inflammatory autoantibodies (in particular, IgG2b and IgG2c), which deposit in the kidney and promote complement activation and tissue destruction.
Vascular sinusoid
A specialized blood vessel in haematopoietic tissues through which venous circulation occurs and that has thin walls formed by a discontinuous, irregularly shaped endothelium that allows cells to pass in and out of the circulation.
link between BAFF overexpression and MyD88-dependent activation of B cells. Indeed, activation of TLR7 and TLR9 strongly upregulated TACI expression 50, 78, 93, 94 , a receptor that is thought to provide positive signals for the maturation or the survival of plasmablasts in T cell-independent type II antibody responses (reviewed in ReF. 48) . These results suggest a tight connection between TLR activation and TACI expression, which might be central to the pathogenic mechanism that triggers autoimmune disease in Baff-transgenic mice (FIG. 5) .
The role of BAFF and APRIL in human diseases
The Baff-transgenic mouse model showed a correlation between excess BAFF and autoimmunity (reviewed in ReF. 31) . Increased levels of BAFF have been measured in patients with various autoimmune conditions, and a correlation with disease progression has frequently been observed (reviewed in ReF. 60) . However, it is unclear whether increased levels of BAFF are a primary cause of autoimmunity or whether autoimmunity is the result of increased production of pro-inflammatory cytokines such as type I IFNs, which are known to promote BAFF production. The role of APRIL in human autoimmunity is unclear, and its circulating levels do not parallel those of BAFF.
It is well established that the levels of BAFF and APRIL in lymphoid cancers are increased (reviewed in ReF. 95) . Lymphoid cancerous cells can produce BAFF as an autocrine survival factor, and APRIL can have a similar role. Interestingly, BAFF expression has recently been detected in non-lymphoid breast cancer cells from epithelial origin 43 , which indicates that the role of BAFF in cancer might be more extensive than first thought. BAFF levels are also increased during inflammation, allergy and viral infection, possibly as a consequence of the production of BAFF inducers such as type I IFNs. This might, in part, explain the occasional autoimmune symptoms that are associated with some viral infections. Thus, the correlation observed between dysregulation of BAFF and APRIL production and disease in humans has extended from autoimmunity and lymphoid cancers to other pathologies, and more work will be required to understand the role of BAFF and APRIL in these diseases.
BAFF and APRIL inhibitors in the clinic
The relevance of BAFF in mouse models of auto immunity, the implication of BAFF and/or APRIL in the survival of lymphoma cells ex vivo and the measure of increased BAFF levels in various pathologies has prompted several clinical trials with BAFF and APRIL antagonists. The most advanced clinical programme is led by Human Genome Sciences (HGS) in partnership with GlaxoSmithKline (GSK). The product, a fully human BAFF-specific monoclonal antibody (belimumab; Lymphostat-B) 96 , has been tested in completed Phase II clinical trials in patients with rheumatoid arthritis and SLE 97 . HGS and GSK have also agreed to test Lymphostat-B in patients with multiple sclerosis, as increased levels of BAFF have been detected in multiple sclerosis lesions 44 and recent results from a Phase II clinical trial with rituximab (a CD20-specific B cell-depleting antibody) indicated clinical benefits from B cell-specific therapies in multiple sclerosis 98 . The second programme is led by ZymoGenetics in partnership with Merck Serono and is testing a TACI-Fc fusion protein (Atacicept), which blocks both BAFF and APRIL (unlike Lymphostat-B) 99 . Phase II and III clinical trials are currently in progress for the treatment of SLE, lupus nephritis, rheumatoid arthritis and relapsing multiple sclerosis. other haematological conditions are being tested in Phase I clinical trials. In general, Atacicept is well tolerated 100 and has a good safety profile. Atacicept seems to be particularly promising for the treatment of SLE and rheumatoid arthritis and it could help patients who are not responding to TNF antagonists.
An important question is whether the targeting of B cells through the BAFF and APRIL system will be as efficient as currently approved treatments for rheumatoid arthritis. Indeed, TNF antagonists and CD20-specific agents have set the bar high, and the lacklustre results from the Lymphostat-B Phase II clinical trial in rheumatoid arthritis indicate that inhibition of BAFF alone might not compare favourably with currently used treatments for rheumatoid arthritis. A caveat (or advantage) of blocking BAFF is that it targets mainly precursor B cell subpopulations rather than established antibody-producing clones or memory B cells 56 . Eliminating the de novo production of self-reactive B cells is crucial, but in some disease settings the elimination of established long-lived memory self-reactive B cells or autoantibody-producing cells might be as important. Another issue is the difference between human and mouse B cells in terms of the requirement of BAFF for survival. BAFF inhibition in non-human primates does not affect the survival of putative transitional B cells, is less potent at eliminating peripheral mature B cells and has little effect on the survival and function of terminally differentiated plasma cells when compared with mice 101, 102 . This could depend on BAFFindependent B cell survival niches such as the niche described in the extravascular compartment of the bone marrow surrounding vascular sinusoids (reviewed in ReF. 103) . Nevertheless, it seems that use of the BAFFspecific inhibitor Lymphostat-B in patients with SLE might be a promising therapeutic avenue.
The effect of blocking BAFF, APRIL and their heteromers with Atacicept rather than with BAFF-specific inhibitors could be different for plasma cells. Indeed, APRIL is implicated in plasma cell survival and antibody production in mice 16, 49 and humans 5 . In addition, mutations in both TACI alleles always result in antibody deficiency
, which indicates that blocking both TACI ligands might be more effective at eliminating antibody-producing cells in humans than BAFF inhibitors or CD20-specific therapies, which are poorly effective on plasma cells.
The treatment of patients with multiple sclerosis with BAFF and/or APRIL inhibitors is an attractive avenue considering the potential role of B cells in the pathology of some patients. Moreover, currently approved IFNβ is controlled by BAFF. The characterization of different biochemical forms of BAFF and APRIL has added a new layer of signalling possibilities through one given receptor, in particular through TACI, which are likely to explain differences in receptor signalling and subsequent biology. Finally, the recent realisation that BAFF, APRIL and their receptors are expressed by a wide range of immune and non-immune cell types is opening a new door of exciting biological possibilities. Development of BAFF and/or APRIL inhibitors in the clinical setting is still strong and ongoing. The main challenge will be to better understand the differences in the BAFF and APRIL system in humans compared with mice and to obtain therapeutic benefits superior to those of currently approved treatments. The future might also show the advantage of combining existing therapies with BAFF and/or APRIL inhibition.
treatments for multiple sclerosis and B cell-depleting agents in patients with autoimmune conditions are both known to increase serum BAFF levels 104, 105 . This raises concerns about potential B cell-specific autoimmune problems associated with these treatments and indicates that combining existing treatments with BAFF inhibitors could improve the outcome in both cases.
Conclusions and perspective
The past decade of studying BAFF and APRIL has led to one of the most important paradigm shifts in B cell immunology. BAFF has emerged as a cytokine that is as important as the BCR in deciding the life or death of a maturing B cell, and great progress has been made in understanding BAFF signalling in B cells. Recent work has also revealed an unappreciated specific role of B cells and innate immune mechanisms in autoimmunity that
